Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Krystexxa Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Krystexxa (pegloticase) Prior Authorization

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity criteria for Krystexxa (pegloticase) 8 mg/mL in adults with chronic gout who are refractory to conventional urate-lowering therapies and meet all stated clinical criteria.

    Policy Summary
    PayerPrime Therapeutics
    PolicyKrystexxa (pegloticase) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing all initial-therapy criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum patient age
    ≥6 mg/dLBaseline serum uric acid
    2 flares/yearSymptomatic gout history
    12 monthsApproval length
    8 mg/mLStrength

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy Criteria

    Pegloticase (Krystexxa) is considered medically necessary when all of the following are met:

    Initial therapy criteria

    • Adult with chronic gout: The patient is 18 years of age or older and has chronic gout≥18 years
    • Baseline hyperuricemia: Baseline serum uric acid is at least 6 mg/dL≥6 mg/dL
    • Symptomatic gout history

      • Recurrent flares: At least two gout flares occurred in the previous year≥2 flares in the previous year
      • Tophus or gouty arthritis: At least one episode of gout tophus or gouty arthritis occurred≥1 episode
    • Refractory to conventional therapy: The patient has a history of contraindication, intolerance, or failure to normalize uric acid to less than 6 mg/dL while receiving conventional therapyUric acid <6 mg/dL

      Conventional therapy may include a xanthine oxidase inhibitor such as allopurinol or febuxostat, or a uricosuric agent such as probenecid

    Initial Krystexxa Authorization

    Initial Krystexxa Authorization

    Krystexxa is medically necessary for chronic gout when all of the following criteria are met:

    Initial Krystexxa authorization

    • Age and diagnosis: The patient is 18 years of age or older and has chronic gout≥18 years
    • Baseline serum uric acid is at least 6 mg/dL≥6 mg/dL
    • Symptomatic disease

      • Gout flares: At least two gout flares occurred in the previous year

    Prior Conventional Therapy

    StepRequired prior therapyQualifying outcome
    1Xanthine oxidase inhibitor, such as allopurinol or febuxostat; or uricosuric agent, such as probenecidContraindication, intolerance, or failure to normalize serum uric acid to less than 6 mg/dL

    Clinical Thresholds

    Baseline serum uric acid
    Required baseline serum uric acidAt least 6 mg/dL
    Target serum uric acid on conventional therapy
    Required treatment-response thresholdLess than 6 mg/dL while receiving conventional therapy
    Gout flare history
    Qualifying gout historyAt least two gout flares in the previous year
    Adult age
    Minimum patient age

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Krystexxa (pegloticase). Approval for initial therapy requires documentation that the adult patient has chronic gout refractory to conventional therapies and meets all applicable clinical criteria.

    • Patient is at least 18 years of age.
    • Baseline serum uric acid (SUA) is at least 6 mg/dL.
    • Patient has symptomatic gout with at least two gout flares in the previous year or at least one episode of gouty tophus or gouty arthritis.
    Step Therapy

    Failure or Intolerance of Conventional Therapy

    Document a history of contraindication, intolerance, or failure of conventional therapy to normalize uric acid to less than 6 mg/dL.

    • Conventional therapy may include a xanthine oxidase inhibitor, such as allopurinol or febuxostat.
    • Conventional therapy may include a uricosuric agent, such as probenecid.

    Policy Background

    Krystexxa (pegloticase) is used to treat chronic gout in adults whose disease is refractory to conventional urate-lowering therapies. Coverage requires documentation of elevated baseline serum uric acid, clinically significant symptomatic gout, and contraindication, intolerance, or failure of conventional therapy to reduce uric acid to less than 6 mg/dL.

    Policy Summary
    PayerPrime Therapeutics
    PolicyKrystexxa (pegloticase) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing all initial-therapy criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaInitial Krystexxa AuthorizationPrior Conventional TherapyClinical ThresholdsAuthorization and Documentation RequirementsPolicy Background
    ≥2 flares in the previous year
  1. Tophus or gouty arthritis: At least one episode of gout tophus or gouty arthritis occurred≥1 episode
  2. Conventional therapy failure, contraindication, or intolerance: The patient has a history of contraindication, intolerance, or failure to normalize uric acid to less than 6 mg/dL while receiving conventional therapyUric acid <6 mg/dL

    Conventional therapy may include a xanthine oxidase inhibitor such as allopurinol or febuxostat, or a uricosuric agent such as probenecid

  3. 18 years of age or older
    Documentation Required

    Medical Record Documentation

    The medical record must support the request with the patient’s clinical history and laboratory results, including the information used to establish refractory chronic gout and eligibility for Krystexxa.

    • Age and diagnosis of chronic gout.
    • Baseline SUA result, documented as at least 6 mg/dL.
    • Gout symptom history, including the number of flares during the prior year and/or documentation of tophus or gouty arthritis.
    • Conventional therapies tried, including the agent, treatment response, and any contraindication or intolerance.
    • Documentation that uric acid failed to normalize to less than 6 mg/dL while receiving conventional therapy, when applicable.
    Denial Risk

    Failure to Meet Clinical Criteria

    Requests are at risk for denial when the required clinical criteria are not documented or cannot be confirmed from the medical record. This includes missing laboratory evidence, insufficient gout symptom history, or failure to establish contraindication, intolerance, or inadequate response to conventional therapy.

    • Baseline SUA below 6 mg/dL or no baseline SUA result documented.
    • Fewer than two gout flares in the previous year and no documented episode of gouty tophus or gouty arthritis.
    • No documented contraindication, intolerance, or failure of conventional therapy to normalize uric acid to less than 6 mg/dL.
    • Patient does not meet the adult age requirement.